Results 271 to 280 of about 53,193 (289)

RET Fusion Testing in Patients With NSCLC: The RETING Study. [PDF]

JTO Clin Res Rep
Conde E, Hernandez S, Rodriguez Carrillo JL, Martinez R, Alonso M, Curto D, Jimenez B, Caminoa A, Benito A, Garrido P, Clave S, Arriola E, Esteban-Rodriguez I, De Castro J, Sansano I, Felip E, Rojo F, Dómine M, Abdulkader I, Garcia-Gonzalez J, Teixido C, Reguart N, Compañ D, Insa A, Mancheño N, Palanca S, Juan-Vidal O, Baixeras N, Nadal E, Cebollero M, Calles A, Martin P, Salas C, Provencio M, Aranda I, Massuti B, Lopez-Vilaro L, Majem M, Paz-Ares L, Lopez-Rios F.   +39 more
europepmc   +1 more source

Cabozantinib Response in a Patient With NSCLC Harboring Both MET Exon 14 Skipping Mutation and Secondary RET Fusion: A Case Report. [PDF]

JTO Clin Res Rep
Torrado C, Feng J, Faour E, Leighl NB.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

RET fusions in solid tumors

Cancer Treatment Reviews, 2019
The RET proto-oncogene has been well-studied. RET is involved in many different physiological and developmental functions. When altered, RET mutations influence disease in a variety of organ systems from Hirschsprung's disease and multiple endocrine neoplasia 2 (MEN2) to papillary thyroid carcinoma (PTC) and non-small cell lung cancer (NSCLC).
Andrew Y. Li, Michael G. McCusker, Alessandro Russo, Katherine A. Scilla, Allison Gittens, Katherine Arensmeyer, Ranee Mehra, Vincenzo Adamo, Christian Rolfo   +8 more
openaire   +2 more sources

RET Fusion Detection Using IdyllaTM Gene Fusion Assay

American Journal of Clinical Pathology, 2023
Abstract Introduction/Objective Non-small cell lung cancer (NSCLC) accounts for 80-85% of lung cancers and RET fusions are detected in 1-2% of NSCLCs, 70% medullary thyroid cancers, 20% papillary thyroid cancers, and <1% of solid tumors.
A Nutcharoen, N Hoo-Fatt, M Nam
openaire   +1 more source

ANKRD26-RET - A novel gene fusion involving RET in papillary thyroid carcinoma

Cancer Genetics, 2019
Rearrangements of RET are drivers of oncogenesis, traceable in different cancer types as papillary thyroid carcinoma (PTC), non-small cell lung cancer, colorectal or breast cancer. Anchored multiplex PCR based next-generation sequencing (NGS) can detect RET rearrangements involving previously unknown partner genes.A sample of PTC underwent NGS ...
Julia Isabelle, Staubitz, Thomas Johannes, Musholt, Arno, Schad, Erik, Springer, Hauke, Lang, Krishnaraj, Rajalingam, Wilfried, Roth, Nils, Hartmann   +7 more
openaire   +2 more sources

RET fusion in the firing line

Nature Medicine, 2021
Selective RET inhibition shows promising anti-tumor activity in patients with RET fusion–positive NSCLC. Selective RET inhibition shows promising anti-tumor activity in patients with RET fusion–positive NSCLC.
openaire   +1 more source